Kuros Biosciences (KURN.SW) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

KURN.SW · Stock Price

CHF 20.42-3.38 (-14.20%)

Market Cap: $1.0B

Historical price data

Market Cap: $1.0BPatents: 7Founded: 2008HQ: Schlieren, Switzerland

Sector Ranking#15 in Regenerative Medicine #57 in Drug Delivery & Formulation

Overview

Kuros Biosciences is a commercial-stage orthobiologics company with a mission to deliver innovative biologic technologies for safer, faster, and more predictable bone healing. The company has achieved a global commercial footprint in over 20 markets and is building a robust Level I clinical evidence package through its Project Fusion research program. Its strategy centers on leveraging its proprietary NeedleGrip™ surface technology to address the significant clinical and economic burden of bone non-unions, aiming to become a leader in the $5B+ bone graft substitute market.

OrthopedicsSpine SurgeryTraumaOncology

Technology Platform

NeedleGrip™ surface technology: a biphasic calcium phosphate ceramic engineered with a needle-shaped submicron topography designed to modulate the immune system (osteoimmunology) to create a pro-healing microenvironment for predictable bone growth.

Funding History

3

Total raised:$52.5M

IPO$35MUndisclosedJun 23, 2017

Series A$15MNovartis Venture FundJun 15, 2005

Seed$2.5MUndisclosedJun 15, 2003

Opportunities

The primary opportunity lies in capturing significant market share in the multi-billion dollar bone graft market by displacing autograft and inferior synthetics with MagnetOs, which has demonstrated superior fusion rates in Level I evidence.

Expansion into high-growth extremities and trauma segments, coupled with compelling health-economic data for payers, provides additional avenues for substantial growth.

Risk Factors

Key risks include intense competition from larger, well-capitalized medical device companies, the challenge of driving rapid surgeon adoption despite strong data, potential reimbursement pressures, and the need to maintain financial discipline while funding global commercial expansion.

Competitive Landscape

Kuros competes in a fragmented market against large conglomerates (Medtronic, Stryker) and pure-play orthobiologics firms. Its primary competitive edge is its proprietary NeedleGrip technology and a robust, evidence-based commercialization strategy centered on Project Fusion, which has generated Level I clinical data showing superiority to autograft—a claim few competitors can make.